Prescription medicine
Hydrochlorothiazide and triamterene First approved as Dyazide
Hydrochlorothiazide and triamterene (Dyazide) is a prescription medicine with an FDA approval on record since 1965. FDA's NDC Directory lists it from 24 generic labelers, and pharmacies paid $0.0969 per triamterene-hydrochlorothiazide 37.5-25 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the hydrochlorothiazide and triamterene FDA label on DailyMed (effective February 17, 2026, Apotex Corp.); the NDA 16042 record on Drugs@FDA; every hydrochlorothiazide and triamterene label on DailyMed.
Highlights of the record
FDA label of February 17, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageThis fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.
Forms and strengths
- 37.5 mg / 25 mg
- 75 mg / 50 mg
Tablet; capsule.
On the market
- Earliest approval on file
- December 2, 1965 Dyazide, Glaxosmithkline Llc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 19 first December 8, 1987; 10 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 24 of which 24 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.0969 per tablet Triamterene-hydrochlorothiazide 37.5-25 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 5 since 2013 0 Class I among all firms' recalls; latest November 9, 2022; 1 more by firms not listed as its makers
- FAERS reports
- 6,109 through July 30, 2026
What is hydrochlorothiazide and triamterene used for?
From the label: indications and usageThis fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). […]
Conditions named in the indications of hydrochlorothiazide and triamterene's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Potassium-sparing Diuretic and Thiazide Diuretic.
Source: FDA drug label (Triamterene and Hydrochlorothiazide), Apotex Corp., effective February 17, 2026 (SPL set bd6c3495-ec70-908b-482a-a979506659e9), via openFDA; the full label on DailyMed
Is there a generic for hydrochlorothiazide and triamterene (Dyazide)?
The FDA approved the first generic hydrochlorothiazide and triamterene on December 8, 1987. 19 generic applications are approved; 10 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists hydrochlorothiazide and triamterene from 24 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1965 earliest approval on file
- 1987 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for hydrochlorothiazide and triamterene (Dyazide)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0969 per Triamterene-hydrochlorothiazide 37.5-25 mg tablet, up 6% from $0.0916 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Triamterene-hydrochlorothiazide 37.5-25 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Triamterene-hydrochlorothiazide 37.5-25 mg capsule | Generic | $0.118 per capsule | $3.54 | -1% |
| Triamterene-hydrochlorothiazide 37.5-25 mg tablet | Generic | $0.0969 per tablet | $2.91 | +6% |
| Triamterene-hydrochlorothiazide 75-50 mg tablet | Generic | $0.131 per tablet | $3.94 | +17% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has hydrochlorothiazide and triamterene been recalled?
The FDA's Enforcement Report lists 6 recalls naming hydrochlorothiazide and triamterene since 2013: 0 Class I (the most serious), 2 Class II, 4 Class III; 0 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of hydrochlorothiazide and triamterene and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| November 9, 2022 | Class III | Lannett Company Inc. | Failed Impurity/Degradation Specifications |
| January 26, 2022 | Class II | CARDINAL HEALTHCARE | CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. |
| July 9, 2018 | Class III | Mylan Pharmaceuticals Inc. | Subpotent Drug |
| April 6, 2018 | Class III | Sandoz Incorporated | Cross Contamination With Other Products: presence of unrelated ingredients (i.e. traces of Lisinopril, Mannitol, Iron, Calcium and Phosphorous). |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: TRIAMTERENE/ HYDROCHLOROTHIAZIDE, Tablet, 37.5 mg/25 mg may have potentially been mislabeled as the following drug: SEVELAMER HCL … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the hydrochlorothiazide and triamterene label say about other medicines?
The hydrochlorothiazide and triamterene label names 7 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amiloride | contraindications | Antikaliuretic Therapy or Potassium Supplementation Triamterene and hydrochlorothiazide should not be given to patients receiving other potassium-conserving agents such as spironolactone, amiloride hydrochloride or other formulations containing triamterene. |
| Calcium chloride | warnings | These include the intravenous administration of calcium chloride solution, sodium bicarbonate solution and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. |
| Indomethacin | drug interactions | Acute renal failure has been reported in a few patients receiving indomethacin and formulations containing triamterene and hydrochlorothiazide. |
| Lithium | drug interactions | Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. |
| Sodium bicarbonate | warnings | These include the intravenous administration of calcium chloride solution, sodium bicarbonate solution and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. |
| Sodium polystyrene sulfonate | warnings | Cationic exchange resins such as sodium polystyrene sulfonate may be orally or rectally administered. |
| Spironolactone | contraindications | Antikaliuretic Therapy or Potassium Supplementation Triamterene and hydrochlorothiazide should not be given to patients receiving other potassium-conserving agents such as spironolactone, amiloride hydrochloride or other formulations containing triamterene. |
Check hydrochlorothiazide and triamterene against other medicines
Source: FDA drug label (Triamterene and Hydrochlorothiazide), Apotex Corp., effective February 17, 2026 (SPL set bd6c3495-ec70-908b-482a-a979506659e9), via openFDA; the full label on DailyMed
What do FAERS reports show for hydrochlorothiazide and triamterene?
The FDA Adverse Event Reporting System holds 6,109 reports that list hydrochlorothiazide and triamterene among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 352 are coded as a death and 1,567 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as hydrochlorothiazide and triamterene?
57 other medicines are given the same way (oral) and in the same FDA class as hydrochlorothiazide and triamterene or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Amiloride | High blood pressure | 2 labelers | $0.190 per tablet 5 mg tablet | No current entry |
| Chlorothiazide | High blood pressure, Edema (fluid retention) | none listed | n/a | A presentation being discontinued |
| Metoprolol | High blood pressure | 64 labelers | $0.085 per tablet 100 mg tablet | A presentation being discontinued |
| Diltiazem | High blood pressure | 42 labelers | $0.144 per capsule 24h ER(cd) 120 mg capsule | A presentation being discontinued |
| Lisinopril | High blood pressure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Propranolol | High blood pressure | 38 labelers | $0.0493 per tablet 20 mg tablet | In shortage |
| Losartan | High blood pressure | 44 labelers | $0.0327 per tablet 50 mg tablet | No current entry |
| Amlodipine | High blood pressure | 42 labelers | $0.0102 per tablet 5 mg tablet | No current entry |
Every medicine labeled for the same conditions as hydrochlorothiazide and triamterene
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does hydrochlorothiazide and triamterene compare with medicines for the same use?
2 side-by-side pages set hydrochlorothiazide and triamterene beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to hydrochlorothiazide and triamterene
- 57 medicines for the same use
- Other potassium-sparing diuretics
- the pharmacologic class, with prices and generics
- Hydrochlorothiazide and triamterene side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other